Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.59 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.59 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | TDO2 | P48775 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933806 | 0.85 | MAP4K4 (0.43) | LPLLIPGDGAT1MAPKAPK2TGFBR1 | |
| SCHEMBL2216147 | 0.85 | LIPG (0.56) | LPLLIPGDGAT1 | |
| SCHEMBL23347389 | 0.85 | LPL (0.40) | LPLLIPGDGAT1MAPKAPK2EGFR | |
| SCHEMBL6224565 | 0.85 | LPL (0.44) | LPLLIPGMAPKAPK2IDO1 | |
| SCHEMBL21315497 | 0.82 | MAPKAPK2 (0.40) | LPLLIPGDGAT1MAPKAPK2TGFBR1 | |
| SCHEMBL20074691 | 0.81 | TGFBR1 (0.42) | LPLLIPGTGFBR1 | |
| SCHEMBL19764832 | 0.81 | LPL (0.39) | LPLLIPGDGAT1EGFR | |
| SCHEMBL15298570 | 0.79 | CYP2A6 (0.39) | LPLLIPGDGAT1MAPKAPK2EGFR | |
| SCHEMBL24625922 | 0.79 | LIPG (0.51) | LPLLIPGDGAT1MAPKAPK2TGFBR1 | |
| SCHEMBL29778746 | 0.79 | LIPG (0.51) | LPLLIPGDGAT1MAPKAPK2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776997-B2 | 3-aryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-03 | — | — | US | disclosed |
| EP-3004094-B1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-3004094-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195333-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122341-A1 | 3-ARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | PNPO, PAH, TNNI3 | LPL 1697/4885LIPG 1282/4885DGAT1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.